Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

Videos

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.	

Grace Dy, MD, medical oncology, Roswell Park Comprehensive Cancer Center, discusses the use of sotorasib (Lumakras) in patients with non–small cell lung cancer (NSCLC) with 

The phase 1/2 CodeBreak 100 trial (NCT03600883) investigated sotorasib in pretreated patients with 

At 2 years of follow-up, which included an additional 48 patients from a phase 1 cohort, the updated objective response rate was about 41%, which fell within the expected range based on initial data, Dy says. Additionally, the median progression-free survival was about 6 months, Dy explains.

The updated results also examined patients who achieved responses during the initial findings, Dy explains. The analysis showed that about 51% of initial responders remained in response for 12 months or longer, and the median duration of response in these patients was 12.3 months, Dy concludes.

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.


Grace Dy, MD

Articles

Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC